Rosiglitazone HClCAS# 302543-62-0 |
- BS-181
Catalog No.:BCC1439
CAS No.:1092443-52-1
- (R)-DRF053 dihydrochloride
Catalog No.:BCC7726
CAS No.:1241675-76-2
- Flavopiridol hydrochloride
Catalog No.:BCC3925
CAS No.:131740-09-5
- SNS-032 (BMS-387032)
Catalog No.:BCC1152
CAS No.:345627-80-7
- Dinaciclib (SCH727965)
Catalog No.:BCC3765
CAS No.:779353-01-4
- PHA-848125
Catalog No.:BCC3839
CAS No.:802539-81-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
| Cas No. | 302543-62-0 | SDF | Download SDF |
| PubChem ID | 9865387 | Appearance | Powder |
| Formula | C18H20ClN3O3S | M.Wt | 393.89 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble in DMSO > 10 mM | ||
| Chemical Name | 5-[[4-[2-[methyl(pyridin-2-yl)amino]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione;hydrochloride | ||
| SMILES | CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3.Cl | ||
| Standard InChIKey | XRSCTTPDKURIIJ-UHFFFAOYSA-N | ||
| Standard InChI | InChI=1S/C18H19N3O3S.ClH/c1-21(16-4-2-3-9-19-16)10-11-24-14-7-5-13(6-8-14)12-15-17(22)20-18(23)25-15;/h2-9,15H,10-12H2,1H3,(H,20,22,23);1H | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Rosiglitazone HCl Dilution Calculator
Rosiglitazone HCl Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.5388 mL | 12.6939 mL | 25.3878 mL | 50.7756 mL | 63.4695 mL |
| 5 mM | 0.5078 mL | 2.5388 mL | 5.0776 mL | 10.1551 mL | 12.6939 mL |
| 10 mM | 0.2539 mL | 1.2694 mL | 2.5388 mL | 5.0776 mL | 6.3469 mL |
| 50 mM | 0.0508 mL | 0.2539 mL | 0.5078 mL | 1.0155 mL | 1.2694 mL |
| 100 mM | 0.0254 mL | 0.1269 mL | 0.2539 mL | 0.5078 mL | 0.6347 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Rosiglitazone is a blood glucose-lowering drugs, stimulating insulin secretion by binding to the PPAR receptors in fat cells.
- Potassium 7-hydroxynaphthalene-1-sulfonate
Catalog No.:BCN8289
CAS No.:30252-40-5
- 1-Hydroxybaccatin I
Catalog No.:BCN5211
CAS No.:30244-37-2
- Ingenol
Catalog No.:BCN2333
CAS No.:30220-46-3
- Effusanin A
Catalog No.:BCN5210
CAS No.:30220-43-0
- Arenobufagin 3-hemisuberate
Catalog No.:BCN7837
CAS No.:30219-16-0
- Retinoic acid
Catalog No.:BCN2185
CAS No.:302-79-4
- DL-Alanine
Catalog No.:BCN8539
CAS No.:302-72-7
- Aconitine
Catalog No.:BCN1014
CAS No.:302-27-2
- Hydroxyprogesterone acetate
Catalog No.:BCC8997
CAS No.:302-23-8
- Desoxyrhaponticin
Catalog No.:BCN2954
CAS No.:30197-14-9
- Ro 5-3335
Catalog No.:BCC7962
CAS No.:30195-30-3
- Boc-Lys(Boc)-OSu
Catalog No.:BCC3415
CAS No.:30189-36-7
- Bisline
Catalog No.:BCN2062
CAS No.:30258-28-7
- 3,4,5-Trimethoxycinnamyl alcohol
Catalog No.:BCN5212
CAS No.:30273-62-2
- TCS 46b
Catalog No.:BCC7482
CAS No.:302799-86-6
- Ciliobrevin A
Catalog No.:BCC3939
CAS No.:302803-72-1
- Ro 01-6128
Catalog No.:BCC7922
CAS No.:302841-86-7
- Ro 67-4853
Catalog No.:BCC7921
CAS No.:302841-89-0
- Dasatinib (BMS-354825)
Catalog No.:BCC1281
CAS No.:302962-49-8
- 2-Amino-N-(2-chloro-6-methylphenyl) thiazole-5-carboxamide
Catalog No.:BCC8551
CAS No.:302964-24-5
- Clinofibrate
Catalog No.:BCC5020
CAS No.:30299-08-2
- Heliotrine
Catalog No.:BCN1982
CAS No.:303-33-3
- Lasiocarpine
Catalog No.:BCN2001
CAS No.:303-34-4
- Methenolone enanthate
Catalog No.:BCC9029
CAS No.:303-42-4
Lack of effect of colesevelam HCl on the single-dose pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin.[Pubmed:24721587]
Diabetes Res Clin Pract. 2014 Jun;104(3):401-9.
AIMS: Drug interactions with bile acid sequestrants are primarily due to the potential of these agents to bind to concomitant drugs. Six clinical studies were performed to determine the effects of colesevelam on the pharmacokinetics of aspirin, atenolol, enalapril, phenytoin, rosiglitazone, and sitagliptin. METHODS: All six studies enrolled healthy subjects aged 18-45 years. The phenytoin study used a single-dose, three-period crossover design (phenytoin alone, phenytoin simultaneously with colesevelam, and phenytoin 4h before colesevelam). The other studies used a two-period crossover design (test drug alone and test drug simultaneously with colesevelam). Colesevelam (3750mg once daily) was dosed throughout the pharmacokinetic sampling period. After each single dose of the test drug, serial blood samples were collected for determination of plasma drug concentrations and calculation of pharmacokinetic parameters. RESULTS: For all six test drugs, 90% CIs for geometric least-squares mean ratios of AUC and Cmax for the measured analytes were within specified limits, indicating no interaction between the test drug and colesevelam. CONCLUSIONS: Aspirin, atenolol, enalapril, rosiglitazone, and sitagliptin may be taken with colesevelam. Although the phenytoin study indicated no pharmacokinetic interaction, phenytoin should continue to be taken >/=4h before colesevelam in accordance with current prescribing information.
